RSSS — FY2026 Annual Report Analysis

Revenue fell 1.5%, but profit more than doubled — the mix did the work

Research Solutions (NASDAQ: RSSS) closed fiscal 2026 on June 30, 2026 with less revenue and far more profit than the year before. Total revenue was $48.31 million, down 1.5% from $49.06 million, while net income rose 123% to $2.82 million ($0.09 per diluted share, up from $0.04).

That combination isn't a paradox. The company sells two very different things, and one of them is roughly three and a half times as profitable as the other:

• Platforms — software subscriptions to Article Galaxy, Scite.ai and related tools, sold mostly to corporate, academic and government research teams on auto-renewing annual contracts. Revenue grew 9.8% to $20.82 million, and it carries an 87.5% gross margin (gross margin = the share of revenue left after the direct cost of delivering the service, before sales, R&D and overhead).
• Transactions — reselling individual scientific, technical and medical (STM) articles, where most of the price paid by the customer goes to the publisher as a copyright fee. Revenue fell 8.7% to $27.49 million, at a 25.0% gross margin.

So the year's trade was: give up $2.62 million of transaction revenue (worth about $0.75 million of gross profit), gain $1.87 million of platform revenue (worth about $1.63 million of gross profit). Net result — gross profit up $0.87 million, or 3.6%, to $25.07 million, on a smaller revenue base. Total gross margin rose 2.6 percentage points to 51.9%, which management attributes directly to "the continued revenue mix shift to the higher-margin Platforms business." Platforms were 43% of revenue (from 39%) and now generate 73% of all gross profit.

Key numbers

ARR (annual recurring revenue) is the company's measure of contracted subscription revenue normalized to a full year — a forward-looking snapshot of the subscription base at a point in time, as opposed to revenue, which is what was actually recognized over the past twelve months. A "deployment" is one B2B platform installation; B2C is the individual-researcher subscription business, mostly Scite.

How much of the profit jump is real

Net income rising 123% overstates the operating improvement, because both years carry noise from the Scite acquisition below the operating line:

• FY2025 absorbed a $1.75 million non-cash charge for an increase in the estimated fair value of the Scite contingent earnout (deferred purchase price owed to Scite's former shareholders).
• FY2026 instead carries $1.04 million of accreted interest expense on that same earnout — once the payout was fixed at $15.4 million as of June 30, 2025, the company began unwinding the discount on the unpaid balance as interest.

Net "other" expense was therefore $0.63 million this year against $1.15 million last year — a $0.52 million tailwind that has nothing to do with the operating business.

The cleaner read is operating income: up $1.09 million to $3.59 million. Decomposing that:

Strip out stock compensation and currency, and cash operating costs actually rose about $0.33 million year over year. The company did not get leaner; it got a better revenue mix and paid out less in stock. G&A fell 15.3% on "lower personnel costs and lower consulting, investor relations, travel, recruiting and bad debt expenses" — bad debt alone swung roughly $164,000 (a $23,000 credit this year against a $141,000 expense last year), which is a one-time-ish benefit, not a structural cost reduction. Meanwhile the money went where you'd want it to: sales and marketing up 19.4% on headcount and consulting, and technology and product development up 8.7%; underlying research and development spending inside those lines rose 24% to $3.13 million.

Adjusted EBITDA — the company's preferred measure, which strips out stock compensation, depreciation, tax and all the earnout noise — rose 10.6% to a record $5.83 million, a 12.1% margin. That 10.6% is the most honest single number for how much better the business performed.

Takeaway: Research Solutions is successfully converting itself from a low-margin article reseller into a software company — each point of mix shift adds roughly 62 cents of gross profit per dollar moved — but the engine driving that shift is slowing: net new B2B deployments fell to 105 from 150, and the consumer subscription base shrank for the first time, turning a +$1.36M ARR contribution in FY2025 into -$0.38M.

The subscription base: growing, but decelerating

B2B ARR ended the year at $16.20 million, up 14.1%. That is the healthiest number in the filing. But the rate of addition is falling:

• Incremental B2B ARR was $2.01 million in FY2026 vs. $2.14 million in FY2025.
• Net new deployments were 105 vs. 150 the year before — a 30% decline in logo/installation growth.
• In the June quarter specifically, incremental B2B ARR was $486,000 against $724,000 a year earlier (-33%), on 29 net new deployments vs. 38.

Because deployment growth slowed more than ARR growth, more of the increase came from price and expansion within existing accounts than from new customers: average selling price per deployment rose 4.7% to $12,698. Management credits "a mix of new logo generation and upsell and cross-sells into the existing customer base," specifically cross-selling Scite into existing Article Galaxy customers. Expansion revenue is generally cheaper to win than new logos, so this is not bad news — but it is a different growth profile than the one implied by the headline 14% ARR figure, and it is happening while sales and marketing spending rises 19%.

The consumer side moved the other way. B2C ARR — individual researchers subscribing to Scite, mostly month-to-month — fell 5.6% to $6.34 million, subtracting $379,000, after adding $1.36 million (+25.3%) in FY2025. That is a genuine reversal in a business that was the growth story a year earlier, and no explanation for it appears in the 10-K.

Why that reversal matters more than its size: the Scite earnout was finalized at $15.4 million using "the ending business to consumer annual recurring revenue figures as of May 30, 2025." The price is locked to a B2C ARR level the business has since fallen below. RSSS will pay the full amount regardless — 62% in cash, 38% in stock, across eight quarterly installments that began in August 2025 and end in May 2027.

Transactions: still shrinking, but the bleeding is slower and cheaper

Transaction revenue fell $2.62 million on "lower paid order volume," which the earnings release places "particularly in the second and third quarters of fiscal 2026." The June quarter was milder: transaction revenue down 6.7% versus the 8.7% full-year decline, and transaction gross margin actually improved in Q4 to 26.0% from 24.1%. For the full year, though, transaction gross margin slipped to 25.0% from 25.3% "primarily due to lower copyright margins" — i.e. publishers took a slightly larger share of each article sale.

Customer counts corroborate the volume story: average active transaction customers fell 3.1% to 1,330, with corporate customers down 5.7% to 993 and academic customers up 5.3% to 337. So the decline is concentrated in corporate R&D buyers — the same customers who buy the platform subscriptions — while academic accounts grew.

Two useful framings. First, the annualized Q4 transaction run-rate is about $27.1 million, essentially level with the $27.5 million full-year figure, which suggests the decline is flattening rather than accelerating. Second, at a 25% margin, each additional 1% of transaction revenue erosion costs only about $69,000 of gross profit — roughly what $79,000 of new platform ARR would replace. The transaction business is large in revenue terms and small in profit terms, which is precisely why revenue can fall while profit rises.

Worth noting on the supply side: the three largest content suppliers accounted for 46% of content cost (45% last year). Those relationships are non-exclusive, and copyright-fee terms set transaction margins directly.

Cash, the earnout, and dilution

Cash ended at $12.63 million, up only $0.40 million despite $5.27 million of operating cash flow, because $4.85 million left through financing — almost entirely earnout settlements.

• Operating cash flow fell 24.9% to $5.27 million. The decline is mostly working-capital timing, not earnings: FY2025 benefited from a $1.68 million deferred revenue build and a $1.07 million release of prepaid royalties, while FY2026 saw a smaller $0.78 million deferred revenue build and a $1.26 million decrease in accounts payable and accrued expenses.
• Capital spending is negligible ($40,000), so free cash flow is roughly $5.23 million — but $4.86 million of cash plus $2.91 million of stock went to Scite's former shareholders this year.
• The remaining earnout liability is $7.32 million (down from $14.05 million). The fifth installment was paid on August 2, 2026: $1.2 million cash and 329,118 shares. Three installments remain, ending May 2027.
• Deferred revenue (subscription cash collected in advance of recognition — a leading indicator of the subscription book) rose 7.3% to $11.49 million, slightly ahead of the 7.8% total ARR growth.
• Diluted share count rose 2.4% to 32.27 million, largely from stock-settled earnout payments. Expect further dilution through May 2027.

There is no debt of consequence: a $500,000 PNC revolving line, undrawn, maturing April 2027. The company still carries a $22.2 million accumulated deficit from its loss-making history, so profitability here is recent and thin.

Outlook

Management gave no formal FY2027 revenue or earnings guidance. CEO Roy Olivier pointed instead to product: two new AI integrations, Scite MCP and Article Galaxy MCP, which let researchers use Scite and Article Galaxy from inside ChatGPT, Claude and Copilot, and which he says have built "a large pipeline of AI related revenue opportunities in FY27." AI-related ARR is currently $0.8 million — about 5% of B2B ARR — but grew 125% sequentially in the June quarter. He also flagged an intent to pursue acquisitions.

My read. The FY2027 arithmetic is reasonably legible. Exiting at $16.20 million of B2B ARR against $20.82 million of recognized platform revenue (which includes B2C), platform revenue should grow high single digits to low double digits without any acceleration in bookings. Transactions, at a Q4 run-rate of roughly $27.1 million, look close to flat-to-slightly-down. That points to total revenue roughly flat to modestly up — the first year the mix shift stops costing revenue — with gross margin continuing to climb a couple of points toward the mid-50s. Adjusted EBITDA should grow faster than revenue again, though less dramatically now that the stock-compensation drop (a $0.80 million one-time help this year) won't repeat.

Two things to watch, in order of importance. First, whether B2B deployment additions re-accelerate. Adding 105 deployments while spending 19% more on sales is the weakest signal in this report; if FY2027 adds fall again while sales spending holds, the mix-shift story runs into a growth ceiling. Second, whether B2C stabilizes. It is only 28% of ARR, but its reversal from +25% to -6% in one year is the kind of move that either reflects competition from general-purpose AI assistants displacing individual Scite subscriptions — a structural threat the 10-K's own risk factors acknowledge, noting "increased competition from other companies that are using GenAI platforms" — or a correction after a promotional surge. The company hasn't said which.

One mechanical tailwind arrives later: the $1.04 million annual accreted interest expense on the earnout ends with the final payment in May 2027, adding roughly that amount to pretax income from FY2028, alongside the end of the cash and share outflows. On $2.8 million of net income, that is not a small item.

---

Source: Research Solutions, Inc. Form 10-K for the fiscal year ended June 30, 2026, filed with the SEC on September 11, 2026 (accession 0001104659-26-107044), and the fiscal fourth quarter and full year 2026 earnings release furnished as Exhibit 99.1 to the Form 8-K filed September 9, 2026. All figures are as reported; Adjusted EBITDA is a non-GAAP measure defined by the company.